Show simple item record

dc.contributor.authorGridelli, Cesare
dc.contributor.authorAapro, Matti S
dc.contributor.authorBarni, Sandro
dc.contributor.authorBeretta, Giordano Domenico
dc.contributor.authorColucci, Giuseppe
dc.contributor.authorDaniele, Bruno
dc.contributor.authorDel Mastro, Lucia
dc.contributor.authorDi Maio, Massimo
dc.contributor.authorDe Petris, Luigi
dc.contributor.authorPerrone, Francesco
dc.contributor.authorThatcher, Nick
dc.contributor.authorDe Marinis, Filippo
dc.date.accessioned2009-06-11T14:16:01Z
dc.date.available2009-06-11T14:16:01Z
dc.date.issued2007-07
dc.identifier.citationRole of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. 2007, 63 (1):53-64 Crit. Rev. Oncol. Hematol.en
dc.identifier.issn1040-8428
dc.identifier.pmid17368037
dc.identifier.doi10.1016/j.critrevonc.2007.01.008
dc.identifier.urihttp://hdl.handle.net/10541/70224
dc.description.abstractFebrile neutropenia is a relatively frequent event in cancer patients treated with chemotherapy. A relevant body of scientific evidence has been produced in the last 2 decades, through clinical trials addressing the efficacy of colony stimulating factors (CSFs) in the prevention and treatment of febrile neutropenia. The correct use of CSFs needs to be optimized, and several guidelines have been produced and periodically updated, in order to uniform and guide clinical practice. The aim of this review is to synthesize the most relevant clinical trials and the most important existing guidelines about the role of CSFs in solid tumours. Role of CSFs as primary prophylaxis, secondary prophylaxis and treatment of afebrile and febrile neutropenia is discussed. A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectColorectal Canceren
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Agents
dc.subject.meshBreast Neoplasms
dc.subject.meshClinical Trials as Topic
dc.subject.meshColony-Stimulating Factors
dc.subject.meshColorectal Neoplasms
dc.subject.meshFemale
dc.subject.meshFever
dc.subject.meshFilgrastim
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshNeutropenia
dc.subject.meshPractice Guidelines as Topic
dc.titleRole of colony stimulating factors (CSFs) in solid tumours: results of an expert panelen
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy. cgridelli@libero.iten
dc.identifier.journalCritical Reviews in Oncology/Hematologyen
html.description.abstractFebrile neutropenia is a relatively frequent event in cancer patients treated with chemotherapy. A relevant body of scientific evidence has been produced in the last 2 decades, through clinical trials addressing the efficacy of colony stimulating factors (CSFs) in the prevention and treatment of febrile neutropenia. The correct use of CSFs needs to be optimized, and several guidelines have been produced and periodically updated, in order to uniform and guide clinical practice. The aim of this review is to synthesize the most relevant clinical trials and the most important existing guidelines about the role of CSFs in solid tumours. Role of CSFs as primary prophylaxis, secondary prophylaxis and treatment of afebrile and febrile neutropenia is discussed. A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record